-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 U8s7l4+uxONsY/boZuusoYqXU7MBblD2waAjycUjmA9fbqGJPUtopl0lTy30W5t1
 0Qs+8ZNWu/RzK43MueYJDA==

<SEC-DOCUMENT>0000885590-10-000067.txt : 20101227
<SEC-HEADER>0000885590-10-000067.hdr.sgml : 20101224
<ACCEPTANCE-DATETIME>20101227154156
ACCESSION NUMBER:		0000885590-10-000067
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20101222
FILED AS OF DATE:		20101227
DATE AS OF CHANGE:		20101227

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Loberg Philip Walden Jr
		CENTRAL INDEX KEY:			0001508799

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		101274212

	MAIL ADDRESS:	
		STREET 1:		31121 BROOKS STREET
		CITY:			LAGUNA BEACH
		STATE:			CA
		ZIP:			92651

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Valeant Pharmaceuticals International, Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		7150 MISSISSAUGA ROAD
		STREET 2:		MISSISSAUGA
		CITY:			ONTARIO
		STATE:			A6
		ZIP:			00000
		BUSINESS PHONE:		905 286-3000

	MAIL ADDRESS:	
		STREET 1:		7150 MISSISSAUGA ROAD
		STREET 2:		MISSISSAUGA
		CITY:			ONTARIO
		STATE:			A6
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2010-12-22</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000885590</issuerCik>
        <issuerName>Valeant Pharmaceuticals International, Inc.</issuerName>
        <issuerTradingSymbol>VRX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001508799</rptOwnerCik>
            <rptOwnerName>Loberg Philip Walden Jr</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O 7150 MISSISSAUGA ROAD</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>MISSISSAUGA</rptOwnerCity>
            <rptOwnerState>A6</rptOwnerState>
            <rptOwnerZipCode>L5N 8M5</rptOwnerZipCode>
            <rptOwnerStateDescription>ONTARIO, CANADA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>EVP, Interim CFO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Restricted Share Units</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2010-12-22</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>671</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, no par value</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>671</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>20671</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each Restricted Share Unit (RSU) represents a contingent right to receive between zero and three shares of Common Stock, no par value, of Valeant Pharmaceuticals International, Inc. (the &quot;Common Stock&quot;), subject to performance based vesting criteria.  See note (3).</footnote>
        <footnote id="F2">Represents dividend equivalents accrued on RSUs as a result of a dividend paid on the Common Stock on December 22, 2010.</footnote>
        <footnote id="F3">The performance based RSUs will vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the prior 20 trading days as of three measurement dates: 25% would vest on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of Common Stock, respectively, with early vesting possible at higher TSR levels.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>By: Angie Palmer for Philip Loberg</signatureName>
        <signatureDate>2010-12-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----